Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Guillermo Montalban-Bravo, Nicholas J. Short, Kelly S. Chien, Yesid Alvarado Valero, Naval Daver, Gautam Borthakur, Mahesh Swaminathan, Abhishek Maiti, Danielle E. Hammond, Graciela Nogueras-Gonzalez, Xuelin Huang, Heather Schneider, Kristen Shelly, Tapan M. Kadia, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1876.

https://doi.org/10.1182/blood-2023-178035

Published: 2023

Journal Articles

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Gautam Borthakur, Zeev Estrov, Tapan M. Kadia, Farhad Ravandi, Naveen Pemmaraju, Graciela Nogueras-Gonzalez, Heather Schneider, Rosmy John, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero, Xiao Qin DONG

Blood (2023) 142 (Supplement 1): 1873.

https://doi.org/10.1182/blood-2023-178110

Published: 2023

Journal Articles

a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Naval Daver, MD, Rita Assi, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Tapan Kadia, MD, Jing Ning, PhD, Graciela Nogueras González, Sherry Pierce, BSN, BA, Mary Kelly, Weiguo Zhang, MD PhD, Dan Gombos, MD, Steven Kornblau, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 1344.

https://doi.org/10.1182/blood.V130.Suppl_1.1344.1344

Published: 2017

Journal Articles

Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML

Blood (2017) 130 (Supplement 1): 2634.

https://doi.org/10.1182/blood.V130.Suppl_1.2634.2634

Published: 2017

Journal Articles

Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML

Ghayas C. Issa, MD, Hagop M. Kantarjian, MD, Feng Wang, PhD, Graciela Nogueras González, Gautam Borthakur, MD, Guilin Tang, MD, Carlos E. Bueso-Ramos, MD PhD, Rashmi Kanagal-Shamanna, MD, Juliana Elisa Hidalgo Lopez, MD, Chong Zhao, Marcus Coyle, Koichi Takahashi, MD, Preetesh Jain, MBBS,MDDM,PhD, Farhad Ravandi, MBBS, Tapan Kadia, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Andrew Futreal, PhD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 47.

https://doi.org/10.1182/blood.V130.Suppl_1.47.47

Published: 2017

Journal Articles

Sequential Stratification Prognostic Score for Patients with Intermediate-Risk Myelodysplastic Syndrome

Christopher B Benton, MD, Maliha Khan, MD, Graciela Nogueras González, Aziz Nazha, MD, Jin Piao, Jing Ning, PhD, Fleur M. Aung, MD, Elias J. Jabbour, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Farhad Ravandi, MBBS, Rami S. Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Michael Andreeff, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2017) 130 (Supplement 1): 4265.

https://doi.org/10.1182/blood.V130.Suppl_1.4265.4265

Published: 2017

Journal Articles

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

Jan A. Burger, MD PhD, Mariela Sivina, PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan Kadia, MD, Zeev Estrov, MD, Graciela Nogueras González, Xuelin Huang, PhD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Lynette Alexander-Williams, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, William G Wierda, MD PhD, Michael J. Keating, MD

Blood (2017) 130 (Supplement 1): 427.

https://doi.org/10.1182/blood.V130.Suppl_1.427.427

Published: 2017

Journal Articles

Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL

Preetesh Jain, MBBS,MDDM,PhD, Jan A. Burger, MD PhD, Graciela Nogueras González, Rashmi Kanagal-Shamanna, MD, Uri Rozovski, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, William G Wierda, MD PhD, Philip A Thompson, MBBS, Nawid Sarwari, MD, Rajyalakshmi Luthra, PhD, Andrew Quesada, Nitin Jain, MD, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 3006.

https://doi.org/10.1182/blood.V130.Suppl_1.3006.3006

Published: 2017

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential — Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome

Blood (2017) 130 (Supplement 1): 4258.

https://doi.org/10.1182/blood.V130.Suppl_1.4258.4258

Published: 2017

Journal Articles

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment

Ghayas C. Issa, Hagop M. Kantarjian, Graciela Nogueras Gonzalez, Gautam Borthakur, Guilin Tang, William Wierda, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Tapan Kadia, Keyur Patel, Raja Luthra, Alessandra Ferrajoli, Guillermo Garcia-Manero, Mary Beth Rios, Sara Dellasala, Elias Jabbour, Jorge E. Cortes

Blood (2017) 130 (19): 2084–2091.

https://doi.org/10.1182/blood-2017-07-792143

Published: 2017

Includes: Supplemental data

Journal Articles

Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation

Blood (2016) 128 (22): 2791.

https://doi.org/10.1182/blood.V128.22.2791.2791

Published: 2016

Journal Articles

Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients

Blood (2016) 128 (22): 1220.

https://doi.org/10.1182/blood.V128.22.1220.1220

Published: 2016

Journal Articles

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

Preetesh Jain, Hagop Kantarjian, Keyur P. Patel, Graciela Nogueras Gonzalez, Rajyalakshmi Luthra, Rashmi Kanagal Shamanna, Koji Sasaki, Elias Jabbour, Carlos Guillermo Romo, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Gautam Borthakur, Zeev Estrov, Farhad Ravandi, Susan O’Brien, Jorge Cortes

Blood (2016) 127 (10): 1269–1275.

https://doi.org/10.1182/blood-2015-10-674242

Published: 2016

Includes: Supplemental data

Journal Articles

Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities

Preetesh Jain, MBBS,MDDM,PhD, Hagop M. Kantarjian, MD, Raja Luthra, PhD, Graciela Nogueras Gonzalez, Elias Jabbour, Koji Sasaki, MD, Carlos Guillermo Romo, MD, Keyur P. Patel, MD PhD, Tapan Kadia, MD, Gautam Borthakur, MD, Zeev Estrov, MD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 598.

https://doi.org/10.1182/blood.V126.23.598.598

Published: 2015

Journal Articles

Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy

Preetesh Jain, MBBS,MDDM,PhD, Michael J. Keating, MD, Charles Cleeland, Sarah Renner, Huang Xuelin, Graciela Nogueras Gonzalez, David M. Harris, William Wierda, MD PhD, Courtney DiNardo, MD, Naveen Pemmaraju, Nitin Jain, MD, Philip Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, Zeev Estrov, MD

Blood (2015) 126 (23): 2943.

https://doi.org/10.1182/blood.V126.23.2943.2943

Published: 2015

Journal Articles

Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium

Elias Jabbour, MD, Koji Sasaki, Mikkael A. Sekeres, MD MS, Rami S Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Roboz J Gail, MD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Tapan Kadia, MD, Courtney D. DiNardo, MD, Xuemei Wang, PhD, Graciela Nogueras-Gonzalez, Gautam Borthakur, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 4641.

https://doi.org/10.1182/blood.V124.21.4641.4641

Published: 2014

Journal Articles

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

Gautam Borthakur, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Graciela Nogueras Gonzalez, Rajyalakshmi Luthra, PhD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Joyce Bass, Mark Brandt, Hagop M. Kantarjian, MD

Blood (2013) 122 (21): 3971.

https://doi.org/10.1182/blood.V122.21.3971.3971

Published: 2013

Journal Articles

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

Koichi Takahashi, Naveen Pemmaraju, Paolo Strati, Graciela Nogueras-Gonzalez, Jing Ning, Carlos Bueso-Ramos, Rajyalakshmi Luthra, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2013) 122 (16): 2807–2811.

https://doi.org/10.1182/blood-2013-03-491399

Published: 2013

Includes: Supplemental data

Journal Articles

Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics

Aziz Nazha, Vijaya R Bhatt, MBBS, Graciela Nogueras-Gonzalez, Tapan Kadia, Jorge E. Cortes, Naval Daver, MD, Guillermo Garcia-Manero, Hagop M. Kantarjian, Gautam Borthakur

Blood (2011) 118 (21): 1495.

https://doi.org/10.1182/blood.V118.21.1495.1495

Published: 2011

NARROW

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML

Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML

Sequential Stratification Prognostic Score for Patients with Intermediate-Risk Myelodysplastic Syndrome

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL

Clonal Hematopoiesis of Indeterminate Potential — Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment

Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation

Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities

Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy

Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only